Prospective Randomized Control Pilot Study to Compare the Role of Injection Cerebrolysin in Operated cases of Degenerative Cervical Myelopathy

What Was Tested

This randomized controlled trial paper looks at Cerebrolysin.

The aim of this study was to analyze role of cerebrolysin in patients of degenerative cervical myelopathy (DCM) managed by surgical modalities.

Why It Was Studied

Cerebrolysin has been extensively researched with variable success in neurodegenerative pathologies.

The researchers present their pilot study which analyzes the role of cerebrolysin in patients of DCM managed by surgical modalities.

Who Took Part

Modified Japanese Orthopedic Association scores (mJOA) and visual analog scale (VAS) were used to document functional outcomes at 3 weeks, 3 months, 6 months, and 1 year.

How the Study Was Run

The researchers set it up as a randomized, placebo-controlled and pilot study.

Because people in this Cerebrolysin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The comparison arm used a placebo, so changes seen with Cerebrolysin could be set against what happens without it.

It is described as a pilot, a small early test of whether a larger Cerebrolysin study would be practical.

This prospective randomized control trial was conducted at a tertiary care institute in Mumbai.

Sixty operated cases of DCM were randomly divided into 2 groups.

The second group was given placebo.

What Was Measured

Topics PubMed links to this paper include Amino Acids, Pilot Projects and Spinal Cord Diseases.

What This Means in Plain Language

The paper is a randomized, placebo-controlled and pilot study of Cerebrolysin.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2022 (Spine), a journal based in United States.

More context: the Cerebrolysin compound page, all human trials.